Back HIV/AIDS

HIV / AIDS

UNAIDS Reports Progress Ahead of World AIDS Day

Sunday, December 1, is the 26th annual observance of World AIDS Day. In advance of the commemoration, UNAIDS issued its 2013 annual report, AIDS by the numbers, showing that most areas of the world have seen accelerated progress against the epidemic, but some are falling behind. The U.S. Congress last week passed the PEPFAR Stewardship and Oversight Act of 2013, extending international HIV/AIDS funding for another 5 years.

alt

Researchers Reveal Structure of HIV Envelope Protein Used to Enter Cells

Scientists have created a sturdier version of HIV's envelope protein, known as Env, which they used to determine a more complete picture of its overall architecture, the National Institutes of Health announced this week. Better understanding of the protein's structure could aid in the development of HIV vaccines or entry inhibitor drugs.

alt

The Lancet/Cell Conference Asks: What Will it Take to Achieve an AIDS-free World?

"What will it take to achieve and AIDS-free world?" was the question on everyone's mind at a small meeting of the same name held November 3-5 at the St. Francis Hotel in San Francisco. A Cell press release stated that the goal of the meeting was to "bridge the gap between researchers and clinicians in a joint effort to identify what needs to be done before an AIDS-free world can go from dream to reality."

alt

CDC Briefing Discusses Complex Causes of Rising HIV Rates Among Young Gay Men

In the lead-up to World AIDS Day, the CDC hosted an LGBT media web briefing on combatting the resurgence of HIV among young gay and bisexual men, in collaboration with the Human Rights Campaign Foundation, the National Black Gay Men's Advocacy Coalition, and New York's Ali Forney Center. Panelist discussed the many social factors -- including homophobia, racism, depression, drug and alcohol use, and homelessness -- that contribute to higher HIV risk among young men who have sex with men.

alt

AAPS Showcases Vaginal Ring with Tenofovir + Contraceptive, Gel Suitable for Vaginal and Rectal Use

A new intravaginal ring delivers both tenofovir for HIV prevention and levonorgestrel for contraception for 3 months, researchers reported at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place this week in San Antonio. Other studies looked at a novel gel for both vaginal and rectal use containing the antiretroviral IQP-0528, and a bio-adhesive vaginal gel combining tenofovir and the anti-herpes drug acyclovir.

alt

HIV Integrase Inhibitor Elvitegravir Approved in European Union

The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences. It is indicated for use in combination antiretriviral regimens containing a ritonavir-boosted protease inhibitor.

alt

HIV Medicine Association Guidelines Emphasize Primary Care Needs of People with HIV on ART

The HIV Medicine Association (HIVMA) of the Infectious Disease Society of America (IDSA) this week released new Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus, focusing on primary care and prevention for HIV positive people on effective antiretroviral therapy (ART). The new guidelines, published in the November 13, 2013, online edition of Clinical Infectious Diseases (in print January 2014) "reflect the fact that people with HIV are now living normal life spans," according to an HIVMA/IDSA press release.

alt